DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
The BRAIN-AF trial examined whether rivaroxaban is superior to placebo in preventing cognitive decline, stroke, or TIA in individuals with AF and a low risk of stroke. Léna Rivard shares the results and future perspectives.
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Sanjiv Shah, MD
Oussama Wazni, MD
Keith Churchwell, MD
Marc Bonaca, MD
